Jane Street’s Aardvark Therapeutics AARD Stock Holding History

Jane Street’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75.4K	Buy	+20,000	New	+$207K	﹤0.01%	10780

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street's AARD Position: Q4 2025 in Review

Jane Street sold out of Aardvark Therapeutics (AARD) in Q4 2025, closing a stake of 19,447 shares — an estimated $258K sold.

Jane Street first reported a position in AARD in Q3 2025 and held it in 1 quarter. The position peaked at $258K in Q3 2025. 66 funds tracked by Wall St. Rank hold AARD as of Q4 2025.

Jane Street reported no remaining Aardvark Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 19,447 Aardvark Therapeutics shares in Q4 2025, an estimated $258K.
Jane Street first reported a position in Aardvark Therapeutics in Q3 2025 and held it in 1 quarter.
Jane Street's Aardvark Therapeutics position peaked at $258K in Q3 2025.
66 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.